期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

人乳头状瘤病毒(HPV)疫苗的研究进展 被引量：3

Progress in Research of HPV Vaccine
下载PDF
导出
摘要 人乳头状瘤病毒(human papillomavirus,HPV)感染是宫颈癌的主要病因。清除HPV感染和阻断由HPV感染所引发的宫颈癌前病变的进展尚缺乏理想的方法。目前,国际上已有20多种HPV相关疫苗已进入动物和临床试验阶段,主要分为预防性疫苗和治疗性疫苗,主要制剂形式是蛋白质、核酸。动物实验和临床试验结果显示HPV疫苗将在预防HPV感染及治疗由感染所引起的相关疾病方面有重要作用。
作者 王小兵 张伟 张叔人
机构地区 中国协和医科大学中国医学科学院肿瘤研究所生物检测中心 中国协和医科大学中国医学科学院肿瘤研究所免疫学研究室
出处 《中国肿瘤生物治疗杂志》 CAS CSCD 2005年第1期80-83,共4页 Chinese Journal of Cancer Biotherapy
关键词 人乳头状瘤病毒 疫苗 宫颈癌
分类号 R730.7 [医药卫生—肿瘤]
  • 相关文献

参考文献19

  • 1Pisani P,Parkin DM,Bray F, et al. Estimates of the worldwide mortality from 25 cancers in 1990[J]. Int J Cancer, 1999, 83(1): 870-873.
  • 2Kirnbauer R,Taub J,Greenstone H, et al. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles[J]. J Virol , 1993, 67(12): 6929-6936.
  • 3Ying H, Zaks TZ, Wang RF, et al. Cancer therapy using a self-replicating RNA vaccine[J]. Nat Med, 1999, 5(7): 823-827.
  • 4Franceshi S. Human papillomavirus: A vaccine against cervical carcinoma uterine[J]. Epidemiol Prev, 2002, 26(3): 140-144.
  • 5Zhang LF, Zhou J, Chen S, et al. HPV6b virus like particles are potent immunogens without adjuvant in man[J]. Vaccine, 2000,18(11-12): 1051-1058.
  • 6Zhou J, Sun XY, Stenzel DJ, et al. Expression of vaccinia recombinant HPV16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV viron-like particles [J]. Virology, 1991,185(1): 251-257.
  • 7Muderspach L, Wilczynski S, Roman L, et al. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive[J]. Clin Cancer Res, 2000, 6(9): 3406-3416.
  • 8Steller MA, Gurski KJ, Murakami M, et al. Cell-mediated immunoligical responses in cervical and vaginal cancer patients immunized with a lapidated epitope of human papillomavirus type 16 E7[J]. Clin Cancer Res, 1998, 4(9): 2103-2109.
  • 9Lacey CJ,Thompson HS, Monteiro EF, et al. Phase II a safety and immunigenicity of a therapeutic vaccine,TA-GW,in persons with genital warts [J]. J Infect Dis, 1999, 179(3): 612-618.
  • 10de Jong A, O'Neill T, Khan AY, et al. Enhancement of human papillomavirus(HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN,an HPV 16 L2E7E6 fusion protein vaccine[J]. Vaccine, 2002, 20(29-30): 3456-3464.

同被引文献29

  • 1李艳佳,齐凤英,左连富,张建慧.重组质粒pcDNA3.1-IL-15转染对小鼠骨髓DC上表面分子的表达及功能的影响[J].细胞与分子免疫学杂志,2005,21(2):222-225. 被引量：5
  • 2张银川,周旭,王玉琳.宫颈癌预防性疫苗的研发现状与挑战[J].微生物学免疫学进展,2006,34(2):67-71. 被引量：2
  • 3陈复兴,李玺,刘军权,张南征,巩新建,徐永茂.肿瘤免疫编辑与免疫治疗[J].医学与哲学（B）,2007,28(4):59-61. 被引量：9
  • 4Li H, Wang Y, Zhou F. Effect of ex vivo-expanded γ/8-T cells combined with galectin-1 antibody on the growth of humancervical cancer xenografts in SCID mice [Jl. Clin Invest Med, 2010, 33 (5) : E280- E289.
  • 5Nedergaard BS, Ladekarl M, Thomsen HF, et al. Low density of CD3^+ , CD4^ + and CD8 ^+ ceils is associated with increased risk of relapse insquamous cell cervical cancer [J]. Br J Cancer, 2007, 97(8) : 1135-1138.
  • 6Liu WM, Fowler DW, Smith P, et al. Pre-treatment with chemo- therapy can enhance the antigenicity and immunogenicity of tumours bypromoting adaptive immune responses [ J]. Br J Canc- er, 2010, 102(1): 115-123.
  • 7Ikarashi Y, Iizuka A, Koshidaka Y et al. Phenotypieal and func- tional alterations during the expansion phase of invariant Valphal4 natural killer T (Valphal4i NKT) cells in mice primed with alpha- galactosylceramide [ J]. Immunology, 2005 , 116 ( 1 ) : 30-37.
  • 8Motohashi S, Nakayama T. Clinical applications of natural killer T cell-based immunotherapy for cancer [J]. Cancer Sci, 2008, 99 (4) : 638-645.
  • 9Kobayashi H, Tanaka Y, Shimmura H, et al. Complete remission of lung metastasis following adoptive immunotherapy using acti- vatedautologous gammadeha T-cells in a patient with renal cell car- cinoma [J]. Anticancer Res, 2010, 30(2): 575-579.
  • 10Prakash MD, Bird CH, Bird PI. Active and zymogen forms of granzyme B are constitutively released from cytotoxic lymphocytesin the absence of target cell engagement [ J ]. Immunol Cell Biol, 2009, 87(3): 249-254.

引证文献3

二级引证文献17

中国肿瘤生物治疗杂志
2005年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部